Related Experiment Video
Updated: Aug 18, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
Three novel cis-acting elements required for efficient plus-strand DNA synthesis of the hepatitis B virus genome
Jehan Lee1, Myeong-Kyun Shin, Hye-Jin Lee
1Department of Biochemistry, Yonsei University, Seoul 120-749, Korea.
Abstract:
Synthesis of the relaxed-circular (RC) DNA genomes of hepadnaviruses by reverse transcriptase involves two template switches during plus-strand DNA synthesis. These template switches require repeat sequences (so-called donor and acceptor sites) between which a complementary strand of nucleic acid is transferred. To determine cis-acting elements apart from the donor and acceptor sites that are required for plus-strand RC DNA synthesis by hepatitis B virus (HBV), a series of mutants bearing a small deletion were made and analyzed for their impact on the viral genome synthesis. We found three novel cis-acting elements in the HBV genome: one element, located in the middle of the minus strand, is indispensable, whereas the other two elements, located near either end of the minus strand, contribute modestly to the plus-strand RC DNA synthesis. The data indicated that the first element facilitates plus-strand RNA primer translocation or subsequent elongation during plus-strand RC DNA synthesis, while the last two elements, although distantly located on the minus strand, act at multiple steps to promote plus-strand RC DNA synthesis. The necessity of multiple cis-acting elements on the minus-strand template reflects the complex nature of hepadnavirus reverse transcription.
Related Concept Videos
DNA Helicases
The Replisome
The synthesis of the leading and lagging strands is a highly coordinated process. To explain this, the “Trombone model” was proposed by Bruce Alberts in 1980. The DNA loop formation starts when a primer is synthesized on the parent lagging strand. The loop grows with the...
Size and Structure of Viral Genomes
Viruses with RNA Genomes
Hepatitis
Antiviral Nucleoside Inhibitors

